Dear Editor

In their publication of the National Institute for Health and Clinical Excellence (NICE) single technology appraisal of eltrombopag, Boyers et al. \[[@CR1]\] report the results of the indirect treatment comparison (ITC) of eltrombopag and romiplostim, conducted by GlaxoSmithKline (GSK) \[the manufacturer of eltrombopag\] and made available to NICE as part of the single technology appraisal of eltrombopag. Subsequent to the appraisal process, GSK identified and corrected a methodological error in this analysis (available at <http://www.gsk-clinicalstudyregister.com> \[study ID: 114014\]). NICE were made aware of this error in November 2010. This correction was not published as part of the original assessment of eltrombopag and is not used in the Boyers et al. publication \[[@CR1]\]. GSK would like to alert the readers of *PharmacoEconomics* to the corrected data and interpretation of this analysis. The nature of the error, the corrected results and the impact on the conclusions of the article are outlined below.

Indirect Comparison Methodology {#Sec1}
===============================

The analysis is the indirect comparison of durable and overall platelet response between eltrombopag and romiplostim based on two trials with romiplostim and one with eltrombopag (RAISE; Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura Study with Eltrombopag). The primary endpoint in the romiplostim studies (the probability of achieving a durable response) \[[@CR2]\] differs from the primary endpoint in RAISE: the odds of achieving a platelet count ≥50\<400 × 10^9^/L \[[@CR3]\]. An indirect comparison of durable and overall response was performed on a post hoc analysis of RAISE and the romiplostim studies applying the Bucher method \[[@CR4]\]. Although the eltrombopag and romiplostim studies were conducted in similar patient populations, there are important differences in study design and in the definitions of response that introduce uncertainty and bias into the comparison. This should be taken into account in any interpretation of the analysis.

The analyses originally provided to NICE and subsequently presented by Boyers et al. \[[@CR1]\] used incorrect efficacy data extracted from a subset of patients in RAISE, which should have been taken from the intent-to-treat (ITT) population.

Corrected Results {#Sec2}
=================

The durable and overall response rates were recalculated using data from the ITT population.

The results of the indirect comparisons of platelet response (eltrombopag compared with romiplostim), updated using the ITT data, are presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. No evidence of a significant difference in the odds of achieving either a durable or an overall response was identified between the eltrombopag and romiplostim treatment groups in analyses of all patients, splenectomized patients and non-splenectomized patients.Table 1Comparison of efficacy between eltrombopag and romiplostim: durable responseTreatmentOR vs. placebo (95% CI)TreatmentOR vs. placebo (95% CI)Indirect comparison eltrombopag vs. romiplostim \[OR (95% CI)\]All subjects Eltrombopag12.69 (4.36, 36.92)Romiplostim40.02 (5.26, 304.70)0.32 (0.03, 3.14)Splenectomized subjects Eltrombopag13.33 (1.66, 107.43)Romiplostim26.77 (1.52, 472.41)0.50 (0.01, 17.32)Non-splenectomized subjects Eltrombopag12.97 (3.72, 45.26)Romiplostim31.25 (3.81, 256.24)0.41 (0.04, 4.80)*OR* odds ratioTable 2Comparison of efficacy between eltrombopag and romiplostim: overall responseTreatmentOR vs. placebo (95% CI)TreatmentOR vs. placebo (95% CI)Indirect comparison eltrombopag vs. romiplostim \[OR (95% CI)\]All subjects Eltrombopag13.96 (6.12, 31.86)Romiplostim64.07 (17.33, 236.82)0.22 (0.05, 1.02)Splenectomized subjects Eltrombopag14.25 (2.98, 68.02)Romiplostim151.63 (8.39, 2741.84)0.09 (0.00, 2.52)Non-splenectomized subjects Eltrombopag14.83 (5.53, 39.76)Romiplostim43.20 (9.27, 201.33)0.34 (0.06, 2.14)*OR* odds ratio

Interpretation {#Sec3}
==============

There is inherent uncertainty in any indirect comparison and such analyses should be treated with caution. There are several additional factors that increase the uncertainty of the analysis in this particular case:The main outcome of the comparison, durable response, was the primary endpoint of the romiplostim studies and a post hoc analysis for eltrombopag; this means that whilst the romiplostim studies were specifically planned to address the aforementioned outcome, RAISE was not.One of the outcomes presented by Boyers et al. \[[@CR1]\] is overall response, which is the sum of 'durable response' and 'transient response'. Durable response was similarly defined in the romiplostim trials and the eltrombopag post hoc analysis: a response in at least six of the last eight visits of the treatment period. However, the definition of 'transient response' was different: a transient response in the romiplostim analysis required a response at any four, weekly visits during the study, whereas the eltrombopag analysis required four *consecutive* weekly visits. In a disease where platelet counts fluctuate, four consecutive responses are more difficult to achieve and this is likely to have biased the ITC against eltrombopag.Whilst the romiplostim study did not allow tapering or interruptions of concomitant immune thrombocytopenic purpura (ITP) medications during the last 12 weeks of study, in RAISE physicians were encouraged to reduce concomitant ITP medications once a stable dose of eltrombopag was achieved. This was more likely to occur towards the end of the trial, when durable response was assessed in the post hoc analysis. Platelet count fluctuations are expected as a result of tapering ITP medications, and this most likely negatively impacted the response estimates for eltrombopag.The number of durable and overall responders in the placebo arm of the romiplostim study was very low. As such, any indirect comparison will be very sensitive to small changes in this event rate.

Conclusion {#Sec4}
==========

The corrected ITC demonstrates that there is no evidence of a statistically significant difference in durable or overall response between eltrombopag and romiplostim for all patients, splenectomized patients or non-splenectomized patients. Results should be interpreted in the context of the significant uncertainty associated with this comparison, in an orphan disease area, where there is a paucity of robust evidence.
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